Pediatricdecongestants_EY[1]

Pediatricdecongestants_EY[1] - Pediatricdecongestants

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
Pediatric decongestants In October 2007, the FDA Nonprescription Drug Advisory Committee and the Pediatric Advisory  Committee recommended that nonprescription cough and cold products containing  pseudoephedrine, dextromethorphan, chlorpheniramine, diphenhydramine, brompheniramine,  phenylephrine, clemastine, or guaifenesin not be used in children less than 6 years of age. In  January 2008, the FDA issued a Public Health Advisory recommending that OTC cough and  cold products not be used in infants and children less than 2 years. An official ruling regarding  the use of these products in children greater than 2 years has not yet been announced. The  FDA recommends that if parents and caregivers use cough and cold products in children  greater than 2 years, labels should be read carefully, caution should be used when  administering multiple products, and only measuring devices specifically designed for use with  medications should be used. While some combination cough/cold products containing these  ingredients are available by prescription only and are not necessarily under scrutiny by the FDA,  clinicians should thoroughly assess each patient's use of similar products, both prescription and  nonprescription, to avoid duplication of therapy and the potential for inadvertent overdose. http://www.mdconsult.com/das/pharm/body/216341322-4/1044173666/full/482 Pediatric decongestants (with adult dosages included): Phenylephrine     Oral dosage:     Adults and Adolescents:  10 mg PO every 4—6 hours, up to 60 mg/day. Elderly:  Cautiously initiate dosage at the lower end of the adult dosage range; the  dose may be increased if needed (see adult dosage). Elderly patients are more  likely to have adverse reactions to sympathetic amines. Children 6—12 years:  5 mg PO every 4—6 hours, up to 30 mg/day. Children 4—5 years:  2.5 mg PO every 4—6 hours, up to 15 mg/day. Children 2—3 years:  Safety and efficacy have not been established. Previously  recommended dosage was 2.5 mg PO every 4—6 hours, up to 15 mg/day. Infants and Children < 2 years:  Safety and efficacy have not been established.  Caution must be used when administering cough and cold products to infants  and young children. Serious adverse events, including death, have been  associated with the misuse of these medications. Oral dosage (tablets containing 10 mg phenylephrine hydrochloride; e.g.,
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 02/18/2012 for the course PAS 600 - 601 taught by Professor Garrubba during the Fall '10 term at Chatham University.

Page1 / 4

Pediatricdecongestants_EY[1] - Pediatricdecongestants

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online